



Press release from Emotra AB (publ)

Göteborg, October 7, 2020

Emotra postpones the publication of its third-quarter report

Emotra AB (“Emotra” or “the Company”) has decided to postpone the publication of its third-quarter report. The Company had previously announced that it would be publishing its third-quarter report on November 5, 2020. However, the board has decided to postpone its publication until November 26, 2020. The reason for this postponement is to enable insiders in the Company to exercise their right to convert subscription warrants into shares.

The conversion period runs from October 9 to October 23 inclusive, 2020.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73-234 41 93, E-post:

daniel@emotra.se

Fel! Hittar inte referenskälla.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB (publ), AstraZeneca BioVentureHub, Pepparedsleden 1,
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, www.emotra.se